Observations placeholder
Leukine
Identifier
019256
Type of Spiritual Experience
Background
A description of the experience
Sargramostim (marketed by Genzyme under the tradename Leukine) is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator.
It is produced in yeast.
Sargramostim is primarily used for myeloid reconstitution after autologous or allogeneic bone marrow transplantation. It is also used to treat neutropenia induced by chemotherapy during the treatment of acute myeloid leukemia. This medication is being investigated in trials to treat Autoimmune Pulmonary Alveolar Proteinosis (PAP). It is also being investigated in combination with oncolytic reovirus in brain cancer.
On January 23, 2008, Bayer informed healthcare professionals of the market withdrawal of the current liquid formulation of sargramostim. The liquid formulation was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change in the formulation to include edetate disodium (EDTA). The original liquid formulation (without EDTA) was returned to the market in the US shortly after the EDTA-containing liquid formulation was withdrawn.
On Jan, 2, 2016: 1,131 people reported to have side effects when taking Leukine. Among them, 8 people (0.62%) have Hallucination.
On Jan, 2, 2016: 1,131 people reported to have side effects when taking Leukine. Among them, 32 people (2.83%) have Death.
Time on Leukine when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 25.00% | 50.00% | 25.00% | 0.00% | 0.00% | 0.00% | 0.00% |